Cancer Research Technology Limited (CRT, the specialist oncology development and commercialisation company) and The University of Barcelona have initiated a collaboration to develop AT514 (serratamolide) and analogues for the treatment of cancer. AT514 is a microbial depsipeptide, identified as an anti-cancer agent by scientists at the University of Barcelona.
